Compare NBIX & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | FMS |
|---|---|---|
| Founded | 1992 | 1996 |
| Country | United States | Germany |
| Employees | N/A | 108165 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 11.6B |
| IPO Year | 1996 | N/A |
| Metric | NBIX | FMS |
|---|---|---|
| Price | $158.82 | $21.67 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 22 | 2 |
| Target Price | ★ $180.91 | $30.00 |
| AVG Volume (30 Days) | ★ 1.1M | 777.0K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 2.57% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $161,626,000.00 | N/A |
| Revenue This Year | $24.73 | N/A |
| Revenue Next Year | $13.14 | $3.83 |
| P/E Ratio | $81.92 | ★ $15.62 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $121.83 | $20.02 |
| 52 Week High | $162.39 | $29.07 |
| Indicator | NBIX | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 70.80 | 45.24 |
| Support Level | $133.96 | $20.96 |
| Resistance Level | $160.08 | $24.02 |
| Average True Range (ATR) | 4.01 | 0.34 |
| MACD | -0.31 | 0.01 |
| Stochastic Oscillator | 69.93 | 32.27 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.